CTLA4-Ig Avidity Enhancement via Multi-Copy Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CTLA4-Ig molecules require high doses and frequent administration to achieve therapeutic effects due to low avidity and potency for B7 antigens, limiting their therapeutic efficacy in inhibiting T-cell activation and immune responses.
Innovation Solution
A clonal Chinese Hamster Ovary cell population is developed to produce CTLA4-Ig molecules with enhanced avidity and potency by integrating multiple copies of the CTLA4-Ig expression cassette into the genome, ensuring stable production and optimal carbohydrate characteristics, resulting in improved binding affinity to CD80 and CD86.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses and frequent administration are used, then therapeutic effects are achieved, but treatment complexity and burden increase
Solution Approach 1:
The patent modifies the molecular structure parameters of CTLA4-Ig by introducing specific amino acid substitutions (e.g., at positions 102, 134, 233, 155, 165) to enhance binding affinity to B7 antigens. This parameter change in molecular structure directly improves therapeutic effectiveness, allowing lower doses and less frequent administration, thereby reducing treatment complexity while maintaining reliability
2Stability of the object's composition
If multiple copies of expression cassette are integrated, then production stability and carbohydrate characteristics improve, but manufacturing complexity increases
Solution Approach 1:
The patent divides the expression system into multiple independent expression cassettes, each containing the CTLA4-Ig gene sequence. By integrating multiple copies of these segmented cassettes into the cell genome, the system achieves enhanced production stability and optimized carbohydrate characteristics while maintaining manageable manufacturing complexity through modular design
3Ease of operation
If lower doses are administered, then treatment burden is reduced, but achieving therapeutic effect becomes more difficult
Solution Approach 1:
The patent changes the binding affinity parameter of CTLA4-Ig through specific amino acid substitutions that increase avidity for B7-1 and B7-2 antigens. This parameter enhancement allows the molecule to achieve therapeutic effects at lower concentrations, making administration easier while maintaining or improving therapeutic reliability
Data Source
AI summary
The invention provides for mammalian cells capable of producing recombinant CTLA4-Ig and variants thereof. The invention also provides for compositions comprising CTLA4-Ig and formulations thereof. The invention further provides for methods for mass-producing CTLA4-Ig from mammalian cells capable of producing this recombinant protein, and for purifying the CTLA4-Ig.